Trial record 1 of 2 for:    MISTIE
Previous Study | Return to List | Next Study

MIS+rtPA for ICH Evacuation (MISTIE)

This study has been completed.
Genentech, Inc.
Emissary International LLC
Information provided by (Responsible Party):
Daniel Hanley, Johns Hopkins University Identifier:
First received: September 21, 2005
Last updated: June 5, 2013
Last verified: June 2013

The purpose of this trial is to determine the safety of using a combination of minimally invasive surgery and clot lysis with rt-PA to remove intracerebral hemorrhage (ICH). The ICES arm of the trial will determine the safety of endoscopic surgery to remove ICH.

Condition Intervention Phase
Intracerebral Hemorrhage
Drug: MIS+Cathflo Activase (drug)
Procedure: Intraoperative stereotactic CT-Guided Endoscopic Surgery
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Minimally Invasive Surgery Plus rtPA for Intracerebral Hemorrhage Evacuation

Resource links provided by NLM:

Further study details as provided by Johns Hopkins University:

Primary Outcome Measures:
  • Mortality [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
  • Procedure related mortality [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
  • Incidence of cerebritis, meningitis [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
  • Rate of rebleeding [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Rate of clot size reduction at Days 4-5 determined by CT scans [ Time Frame: 7 days ] [ Designated as safety issue: No ]
  • 90-, 180-, & 365-day GOS, eGOS, Rankin, Stroke Impact Scale [ Time Frame: 365 days ] [ Designated as safety issue: No ]
  • Post-operative size reduction [ Time Frame: 10 days ] [ Designated as safety issue: No ]

Enrollment: 143
Study Start Date: August 2005
Study Completion Date: April 2013
Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Medical Managment
Active Comparator: MISTIE Surgical Management
Minimally invasive surgery with clot lysis with rt-PA.
Drug: MIS+Cathflo Activase (drug)
The intervention is a comparison of the safety and preliminary effectiveness of investigational minimally invasive surgery to place a catheter into an intracerebral hemorrhage blood clot and subsequent administration in sequential tiers of 0.3, 1.0, or 3.0 mg of recombinant tissue plasminogen activator, rt-PA, CathFlo®) through the catheter once every eight hours for up to 72 hours with best medical care.
Other Name: rtPA
Active Comparator: ICES Surgical Management
Endoscopic removal of ICH
Procedure: Intraoperative stereotactic CT-Guided Endoscopic Surgery

Detailed Description:

The purpose of this trial is to determine the safety of using a combination of minimally invasive surgery and clot lysis with rt-PA to remove intracerebral hemorrhage (ICH). The procedure is to use image-based surgery (MRI or CT) to provide catheter access to ICH for the intervention, which is a one-time clot aspiration followed by instillation of rt-PA over 72 hours.

The Intraoperative stereotactic CT-guided Endoscopic Surgery (ICES) arm of the trial will determine the safety, feasibility and effectiveness of endoscopic surgery to remove ICH.

We propose to test if these interventions facilitate more rapid and complete recovery of function and decreased mortality from this condition compared to conventional medical management without subjecting the patient to craniotomy. The specific objective of this trial is to test the safety of these interventions and assess their ability to remove blood clot from brain tissue.


Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18-80
  • GCS < 14 or a NIHSS > or equal to 6
  • Spontaneous supratentorial ICH > or equal to 20cc
  • Symptoms less than 12 hours prior to diagnostic CT scan (an unknown time of symptom onset is exclusionary)
  • Intention to initiate surgery within 48 hours after diagnostic CT
  • First dose can be given within 54 hours after diagnostic CT (delays for post surgical stabilization of catheter bleeding or because of unanticipated surgical delay are acceptable with approved waiver from the coordinating center) (Does not apply to ICES Tier)
  • Six-hour clot size equal to the most previous clot size + 5 cc (as determined by an additional CT scan at least 6 hours after the initial stability scan (A*B*C)/2 method)
  • SBP < 200 mmHg sustained for 6 hours recorded closest to time of randomization
  • Historical Rankin score of 0 or 1
  • Negative pregnancy test

Exclusion Criteria:

  • Infratentorial hemorrhage (any involvement of the midbrain or lower brainstem as demonstrated by radiograph or complete third nerve palsy)
  • Patients with platelet count < 100,000, INR > 1.4, or an elevated PT or APTT (reversal of coumadin is permitted but the patient must not require coumadin during the acute hospitalization). Irreversible coagulopathy either due to medical condition or prior to randomization
  • Clotting disorders
  • Any concurrent serious illness that would interfere with the safety assessments including hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, immunologic, and hematologic disease
  • Patients with a mechanical valve
  • Patients with unstable mass or evolving intracranial compartment syndrome
  • Ruptured aneurysm, AVM, vascular anomaly
  • Greater than 80 years (higher incidence of amyloid)
  • Under 18 years of ag e (high incidence of occult vascular malformation)
  • Pregnant (positive pregnancy test) or lactating females (likelihood of altered coagulation function associated with the high estrogen/progesterone state)
  • Irreversibly impaired brainstem function (bilateral fixed, dilated pupils and extensor motor posturing), GCS less than or equal to 4
  • Historical Rankin score greater than or equal to 2
  • Intraventricular hemorrhage requiring external ventricular drainage
  • Internal bleeding, involving retroperitoneal sites, or the gastrointestinal, genitourinary, or respiratory tracts (Does not apply to ICES Tier)
  • Superficial or surface bleeding, observed mainly at vascular puncture and access sites (e.g., venous cutdowns, arterial punctures) or site of recent surgical intervention (Does not apply to ICES Tier)
  • Known risk for embolization, including history of left heart thrombus, mitral stenosis with atrial fibrillation, acute pericarditis, and subacute bacterial endocarditis (Does not apply to ICES Tier)
  • In the investigator's opinion, the patient is unstable and would benefit from a specific intervention rather than supportive care plus or minus MIS+rtPA
  • Prior enrollment in the study
  • Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated
  • Participation in another simultaneous trial of ICH treatment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00224770

  Hide Study Locations
United States, Alabama
University of Alabama at Birmingham
Birmingham, Alabama, United States
United States, Arizona
Barrow Neurosurgical Associates
Phoenix, Arizona, United States, 85013
United States, California
University of California Los Angeles
Los Angeles, California, United States, 90095
Stanford University
Palo Alto, California, United States, 94034
University of California, San Diego
San Diego, California, United States, 92103
United States, Connecticut
Hartford Hospital
Hartford, Connecticut, United States, 06102
United States, District of Columbia
Georgetown University
Washington, District of Columbia, United States, 20007
United States, Florida
Mayo Clinic
Jacksonville, Florida, United States, 32216
United States, Illinois
Rush University
Chicago, Illinois, United States, 60612
University of Chicago
Chicago, Illinois, United States, 60637
NorthShore University Health System
Evanston, Illinois, United States, 60201
United States, Maryland
Johns Hopkins University/Bayview Medical Center
Baltimore, Maryland, United States, 21287
University of Maryland Medical Systems
Baltimore, Maryland, United States, 21201
United States, Michigan
Henry Ford Health System
Detroit, Michigan, United States, 48202
United States, New Jersey
New Jersey Medical School
Edison, New Jersey, United States, 08818
United States, New York
Mt. Sinai Medical Center
New York, New York, United States, 10029
United States, Ohio
University of Cincinnati
Cincinnati, Ohio, United States, 45267
Case Western University
Cleveland, Ohio, United States, 44106
United States, Pennsylvania
Temple University
Philadelphia, Pennsylvania, United States, 19140
Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15213
Allegheny General Hospital
Pittsburgh, Pennsylvania, United States, 15212
United States, South Carolina
Medical University of South Carolina
Charleston, South Carolina, United States, 29425
United States, Texas
University of Texas, Houston
Houston, Texas, United States, 77030
University of Texas HSC, San Antonio
San Antonio, Texas, United States, 78229
United States, Virginia
Virginia Commonwealth University
Richmond, Virginia, United States, 23298
Canada, Quebec
Montreal Neurological Institute at McGill University
Montreal, Quebec, Canada, H3A 2B4
University of Heidelberg
Heidelberg, Germany, 69117
United Kingdom
Newcastle General Hospital
Newcastle, United Kingdom
Sponsors and Collaborators
Daniel Hanley
Genentech, Inc.
Emissary International LLC
Study Chair: Daniel F. Hanley, MD Johns Hopkins University
Principal Investigator: Mario Zuccarello, MD University of Cincinnati
Principal Investigator: Paul Vespa, MD University of California, Los Angeles
  More Information

Additional Information:
No publications provided

Responsible Party: Daniel Hanley, MD, Johns Hopkins University Identifier: NCT00224770     History of Changes
Other Study ID Numbers: ICH01, R01NS046309
Study First Received: September 21, 2005
Last Updated: June 5, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Cerebral Hemorrhage
Brain Diseases
Cardiovascular Diseases
Central Nervous System Diseases
Cerebrovascular Disorders
Intracranial Hemorrhages
Nervous System Diseases
Pathologic Processes
Vascular Diseases
Tissue Plasminogen Activator
Cardiovascular Agents
Fibrin Modulating Agents
Fibrinolytic Agents
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses processed this record on May 21, 2015